MESENCHYMAL STEM CELL THERAPIES FOR POST-COVID-19 LUNG INJURY: REVIEW OF EFFICACY AND SAFETY

Abstract

This article examines the use of mesenchymal stem cells in the treatment of post-COVID-19 lung injuries, evaluating their efficacy and safety. A literature search was conducted for articles published in the last five years. This study demonstrated that mesenchymal stem cell therapies have significant therapeutic potential in the context of post-COVID-19 respiratory sequelae, both in preclinical models and in clinical trials. The findings indicate that MSCs act multifacetedly, promoting anti-inflammatory effects, modulating the immune response, and stimulating lung tissue regeneration, all crucial factors for the functional recovery of patients with severe respiratory injuries. This finding corroborates the importance of continued investment in research focused on cell therapy, enabling the development of protocols that maximize clinical benefits and minimize potential risks. This study demonstrated that mesenchymal stem cell therapies have significant therapeutic potential in the context of post-COVID-19 respiratory sequelae, both in preclinical models and in clinical trials. The findings indicate that MSCs act in a multifaceted manner, promoting anti-inflammatory effects, modulating the immune response, and stimulating lung tissue regeneration, all crucial factors for the functional recovery of patients with severe respiratory injuries. This finding corroborates the importance of continued investment in research focused on cell therapy, enabling the consolidation of protocols that maximize clinical benefits and minimize potential risks.